SCHEDULE: ARCH Venture Funds Boost Stake in Neumora Therapeutics

ARCH Venture Fund XII increased its holdings in Neumora Therapeutics, Inc. by purchasing 1.9 million shares for approximately $5 million.

Summary

• ARCH Venture Fund XII (AVF XII) acquired an additional 1,915,700 shares of Neumora Therapeutics, Inc. common stock.
• The purchase was made on October 27, 2025, at a price of $2.61 per share.
• The total consideration paid by AVF XII for this transaction was $4,999,981.50, funded by its working capital.
• Following this acquisition, various ARCH entities and associated individuals collectively beneficially own 33,847,838 shares, representing 20.6% of Neumora Therapeutics' common stock.
• Kristina Burow's beneficial ownership, including direct shares and options, totals 33,958,967 shares, or 20.7% of the class.
• Clinton Bybee beneficially owns 3,708,794 shares, representing 2.3%.
• Steven Gillis beneficially owns 31,526,272 shares, representing 19.2%.
• The beneficial ownership percentages are calculated based on 163,964,887 shares of Common Stock outstanding, as reported by the Issuer.

Sentiment

Score: 7

Explanation: The increased stake by a major venture capital firm like ARCH Venture Funds is generally a positive signal, indicating continued investor confidence in Neumora Therapeutics. However, this filing is purely an ownership disclosure and does not provide operational or financial performance updates.

Positives

• A significant institutional investor, ARCH Venture Fund XII, increased its stake in Neumora Therapeutics, indicating continued confidence in the company.
• The purchase of 1,915,700 shares for nearly $5 million demonstrates a substantial investment.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding Neumora Therapeutics' future operations or financial performance.

Industry Context

The increased stake by ARCH Venture Funds, a prominent life sciences investor, suggests continued interest and potential confidence in the biotechnology and pharmaceutical sector, particularly in companies like Neumora Therapeutics that are developing novel therapies. This move could be seen as a strategic long-term investment in the sector's growth potential.

Comparison to Industry Standards

• This filing primarily details an ownership change by a venture capital firm. It does not provide operational or financial results that can be directly compared to industry benchmarks or specific comparable companies/projects.
• A significant stake (over 20%) by a major venture fund like ARCH is a common characteristic of early-stage or growth-stage biotech companies where venture capital plays a crucial role in funding and strategic guidance.

Related Party Transactions

• The filing details the complex ownership structure where various ARCH Venture Funds and their general partners (LPs and LLCs) are affiliated entities with overlapping general partners and managing directors.
• Individuals like Robert Nelsen, Keith Crandell, Clinton Bybee, Kristina Burow, and Steven Gillis are associated with these ARCH entities and are reporting persons, indicating their indirect beneficial ownership through these funds.
• Kristina Burow and Steven Gillis have pecuniary interests in certain ARCH entities, and Burow also holds direct shares and options in Neumora Therapeutics.

Stakeholder Impact

• Shareholders: The increased stake by a significant institutional investor could be viewed positively, potentially signaling long-term confidence and stability.
• Management: Continued strong backing from a major venture capital firm like ARCH can provide strategic support and resources.
• Employees: No direct impact mentioned, but strong investor backing can contribute to company stability and growth prospects.

Key Dates

Recommendation

While the increased stake by ARCH Venture Funds is a positive indicator of institutional confidence, this filing is an ownership disclosure and does not provide new information on Neumora Therapeutics' operational performance, pipeline progress, or financial health. Therefore, a 'hold' recommendation is appropriate, awaiting further fundamental updates from the company to assess its intrinsic value and future prospects.

Keywords

Neumora Therapeutics, ARCH Venture, Schedule 13D, Common Stock, Beneficial Ownership, Institutional Investment, Biotechnology, Pharmaceuticals, Venture Capital, Equity Stake